Analysis of Predictive Factors for Efficacy of Yiqi Yangxue Prescription Combined with Western Medicine in Treatment of Aplastic Anemia in Non-elderly Adults
10.13422/j.cnki.syfjx.20232027
- VernacularTitle:益气养血方联合西药治疗非老年成人再生障碍性贫血疗效预测因素分析
- Author:
Chaochang ZHANG
1
;
Rui LI
1
;
Jian LIU
1
;
Yubin DING
2
;
Jinhuan WANG
3
;
Qifeng LIU
4
;
Ruirong XU
5
;
Haixia WANG
6
;
Haixia DI
7
;
Antao SUN
8
;
Yonggang XU
1
;
Xiupeng YANG
1
;
Feng LIU
1
;
Rou MA
1
;
Xudong TANG
1
Author Information
1. Xiyuan Hospital， China Academy of Chinese Medical Sciences， Beijing 100091， China
2. Shenzhen Traditional Chinese Medicine （TCM） Hospital， Shenzhen 518033， China
3. First Affiliated Hospital， Heilongjiang University of Chinese Medicine， Harbin 150040， China
4. Jilin Province People's Hospital， Changchun 130021， China
5. The Affiliated Hospital of Shandong University of TCM， Jinan 250011， China
6. Affiliated Hospital of Weifang Medical University， Weifang 261041， China
7. Langfang TCM Hospital， Langfang 065000， China
8. Guang’anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053， China
- Publication Type:Journal Article
- Keywords:
aplastic anemia;
Yiqi Yangxue prescription;
treatment with integrated traditional Chinese and western medicine;
predictive factors
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(20):88-98
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the predictive factors for the efficacy of Yiqi Yangxue prescription combined with western medicine in treating aplastic anemia （AA） in non-elderly adults， so as to provide a reference for predicting the prognosis of this therapy. MethodA retrospective study was conducted with the clinical data of non-elderly adult AA patients who visited 19 hospitals including Xiyuan Hospital of the China Academy of Chinese Medical Sciences from September 2018 to March 2021 and were treated with Yiqi Yangxue Prescription combined with western medicine. According to the efficacy evaluation results at the 6th month of treatment， the patients were assigned into effective and ineffective groups. The two groups were compared in terms of the gender， age， disease classification ［non-severe aplastic anemia （NSAA）/severe aplastic anemia （SAA）］， course of disease， family history， complications， history of drug allergy， baseline blood routine examination ［hemoglobin （HGB）， white blood cell （WBC）， neutrophil （ANC）， platelet （PLT）， and reticulocyte （Ret）］， T lymphocyte subsets， degree of proliferation of nucleated cells in bone marrow， and expression of T-bet and GATA-3. ResultA total of 101 non-elderly adult AA patients were enrolled in this study， including 81 in the effective group and 20 in the ineffective group. The effective group had a higher proportion of the patients without a history of drug allergy than the ineffective group （P<0.05）. The body height， body weight， gender， age， disease classification， course of disease， family history， and complications showed no significant differences between two groups. The effective group had higher levels of ANC and PLT before treatment （P<0.05） and higher proportion of patients with ANC≥1.6×109/L and PLT≥25×109/L （P<0.05， P<0.01） than the ineffective group. The baseline levels of WBC， HGB， and Ret showed no significant statistical differences between two groups. The levels of CD3+HLA-DR+T cells in the effective group before treatment was higher than that in the ineffective group （P<0.05）. The levels of CD3+CD19-T cells， CD4+T cells， CD8+T cells， Th1 cells， Th2 cells， and CD3+CD25+T cells showed no significant statistical differences between two groups before treatment. The proportion of patients with active bone marrow nucleated cells proliferation in the effective group before treatment were significantly higher than that in the ineffective group, while the proportion of patients with reduced or extremely reduced proliferation were significantly lower than that in the ineffective group （P<0.05）. The expression levels of T-bet and GATA-3 genes had no significant differences between two groups before treatment. The multivariate binary logistic regression analysis showed that the ANC level before treatment and history of drug allergy were independent influencing factors for efficacy （P<0.05， P<0.01）， while other indicators were not influencing factors for efficacy. The receiver operating characteristic （ROC） curve was applied to analyze the predictive value of the ANC level before treatment in the treatment of AA in non-elderly adults with Yiqi Yangxue prescription combined with western medicine. The area under the curve was 0.679 （P<0.05）， with the critical value of 1.595×109/L， the sensitivity of 0.42， and the specificity of 0.95. ConclusionThe history of drug allergy， pre-treatment ANC， PLT， CD3+HLA-DR+ T cell levels， and proliferation of nucleated cells in bone marrow before treatment are predictive factors for the efficacy of Yiqi Yangxue prescription combined with western medicine in treating AA in non-elderly adults. This therapy tends to be more effective for the patients with no history of drug allergy， higher ANC and PLT levels before treatment， especially those with ANC≥1.6×109/L， PLT≥25×109/L， and higher CD3+ HLA-DR+T cell levels and the more active proliferation of nucleated cells in bone marrow before treatment.
